The carbon footprint appraisal of local visitor travel in Brazil: A case of the Rio de Janeiro-São Paulo itinerary

Tourism transportation contributes substantially to the global carbon footprint. This contribution is predicted to enlarge, especially in ‘emerging’ tourism markets, and hence urgent carbon mitigation is necessary. Effective mitigation is determined by reliable carbon footprint assessments whose number is however limited, particularly for developing countries with growing tourism. This study applied the life cycle assessment (LCA) based method to appraise the carbon significance of various transport modes between Rio de Janeiro and São Paulo, the key itinerary for travel with leisure and tourism purposes by local residents and overseas visitors in Brazil. Given the envisaged rise in biofuel use in the Brazilian transportation sector, this study is unique in that it evaluated the carbon reduction potential offered by biofuel. The study demonstrated that overland public transport represents the most carbon-efficient mode of local transportation. It further highlighted the crucial role of biofuel in minimising the carbon intensity of transportation between Rio de Janeiro and São Paulo. Policy-making and managerial recommendations were put forward to facilitate more climate-benign local transportation practices

Applying the facility location problem model for selection of more climate benign mega sporting event hosts: A case of the FIFA World Cups.

Sporting mega-events generate substantial carbon footprint where return transportation of event participants and visitors between the source and host countries makes the largest contribution. To enhance environmental sustainability of sporting mega-events, it is paramount to select a host country with the lowest carbon footprint from international transportation without compromising the magnitude of major visitor flows. The Facility Location Problem (FLP) model represents an established tool employed in the business environment to determine the best location for the installation of facilities to provide for existing or envisaged consumer demand. The model has proven its feasibility in a number of economic sectors, but rarely been applied in tourism, and never with sustainability management and planning purposes. This study contributes to knowledge by demonstrating the applicability of the FLP model when planning for sporting mega-events. The model enables selection of a host country with better climate credentials by quantifying the magnitude of international transportation of the event participants alongside the associated carbon footprint. Application of the FLP model to the FIFA World Cups shows that, to facilitate the progress of these mega-events towards sustainability, a decision on a host country should be made after the team qualification round, rather than before, as it currently stands. The model can then identify prospective hosts with the lowest carbon footprint from international transportation

Antiinflammatory therapy with canakinumab for atherosclerotic disease

BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. Copyright © 2017 Massachusetts Medical Society